India, April 27 -- Late last year, EssilorLuxottica announced the US Food and Drug Administration (FDA) granted market authorisation for its Essilor(R) Stellest(R) lens using the De Novo pathway.

This follows the product's earlier recognition with the FDA granting designation as a Breakthrough Technology in 2021. The Essilor(R) Stellest(R) lens is the first and only US FDA market authorised spectacle lens to slow myopia progression in children.

The effectiveness of the Essilor(R) Stellest(R) lens is evidenced by clinical data showing that the lens slowed down myopia progression by 71% on average over two years. 

The sharp rise in myopia is a growing concern in India, with nearly 50% of urban children projected to be affected by 20...